These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 28701470)

  • 21. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial.
    Núñez J; Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Lupón J; Navarro J; Górriz JL; Sanchis J; Chorro FJ; Comín-Colet J; Bayés-Genís A;
    J Am Heart Assoc; 2020 Feb; 9(4):e014254. PubMed ID: 32067585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
    Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
    Van Tassell BW; Canada J; Carbone S; Trankle C; Buckley L; Oddi Erdle C; Abouzaki NA; Dixon D; Kadariya D; Christopher S; Schatz A; Regan J; Viscusi M; Del Buono M; Melchior R; Mankad P; Lu J; Sculthorpe R; Biondi-Zoccai G; Lesnefsky E; Arena R; Abbate A
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
    Martens P; Dupont M; Dauw J; Nijst P; Herbots L; Dendale P; Vandervoort P; Bruckers L; Tang WHW; Mullens W
    Eur Heart J; 2021 Dec; 42(48):4905-4914. PubMed ID: 34185066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis.
    Dalal J; Katekhaye V; Jain R
    Indian Heart J; 2017; 69(6):736-741. PubMed ID: 29174251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
    JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
    Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh TA; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD
    ESC Heart Fail; 2014 Sep; 1(1):52-58. PubMed ID: 28834668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
    Hofmarcher T; Borg S
    J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
    BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
    Martens P; Dupont M; Dauw J; Somers F; Herbots L; Timmermans P; Verwerft J; Mullens W
    ESC Heart Fail; 2019 Dec; 6(6):1208-1215. PubMed ID: 31562751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study.
    Favrat B; Balck K; Breymann C; Hedenus M; Keller T; Mezzacasa A; Gasche C
    PLoS One; 2014; 9(4):e94217. PubMed ID: 24751822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.
    López-Vilella R; Lozano-Edo S; Arenas Martín P; Jover-Pastor P; Ezzitouny M; Sorolla Romero J; Calvo Asensio M; Martínez-Solé J; Guerrero Cervera B; Sánchez Martínez JC; Donoso Trenado V; Sánchez-Lázaro I; Martinez Dolz L; Almenar Bonet L
    ESC Heart Fail; 2022 Feb; 9(1):133-145. PubMed ID: 34964300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
    Butler J; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Dorigotti F; Metra M; Piña IL; Coats AJS; Rosano G; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Anker SD; Ponikowski P
    Eur J Heart Fail; 2022 May; 24(5):821-832. PubMed ID: 35279929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.
    Ambrosy AP; Lewis GD; Malhotra R; Jones AD; Greene SJ; Fudim M; Coles A; Butler J; Sharma A; Hernandez AF; Mentz RJ
    J Cardiovasc Med (Hagerstown); 2019 Apr; 20(4):223-225. PubMed ID: 30540649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
    Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
    Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial.
    Del Canto I; Santas E; Cardells I; Miñana G; Palau P; Llàcer P; Fácila L; López-Vilella R; Almenar L; Bodí V; López-Lereu MP; Monmeneu JV; Sanchis J; Moratal D; Maceira AM; de la Espriella R; Chorro FJ; Bayés-Genís A; Núñez J;
    J Am Heart Assoc; 2022 Apr; 11(7):e022214. PubMed ID: 35301854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
    Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.